4.5 Article

Genetic factors influencing age at onset in LRRK2-linked Parkinson disease

期刊

PARKINSONISM & RELATED DISORDERS
卷 15, 期 7, 页码 539-541

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2008.10.008

关键词

Parkinson's disease; LRRK2; AAO; MAPT

资金

  1. National Genome Network [NGFN
  2. 01GS0116]
  3. Competence Network Parkinson [01GI0201]
  4. Morris K. Udall Center for Excellence in Parkinson's disease Research at Mayo Clinic Jacksonville [P50 NS40256]
  5. Canadian Institutes of Health Research
  6. Canada Research Chairs program
  7. James & Donna-Mae Moore endowment of the Michael Smith Foundation for Health Research

向作者/读者索取更多资源

Patients with Leucine-rich repeat kinase 2 (LRRK2) linked Parkinson's disease (PD) clinically present with typical idiopathic PD. However, LRRK2-linked PD displays a pleomorphic neuropathology and high variability in age at disease onset (AAO) which suggests that environmental and/or genetic factors other than the mutation itself influence the Course of the disease. We investigated the modulation of AAO by genetic factors including the mutation-containing domain and PD associated polymorphisms in the gene coding alpha-synuclein (SNCA) and tau (MAPT) in 44 patients from 19 affected families. Using this limited number of available LRRK2 mutation carriers, we provide evidence that mutations in the kinase domain of Lrrk2 significantly decrease AAO compared to mutations in the ROC (Ras/GTPase of complex proteins) domain. Furthermore, polymorphic variations in MAPT show a significant association with AAO in individuals with LRRK2 mutations. Our results await replication in future Studies with a larger number of LRRK2 mutation carriers, but indicate an association of mutation-affected protein domain and mutation-extrinsic genetic factors with AAO and suggest that these factors could Contribute to explain the phenotypic heterogeneity observed in LRRK2-linked PD. (C) 2008 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Characterizing mixed location hemorrhages/microbleeds with CSF markers

Ulf Jensen-Kondering, Nils G. Margraf, Caroline Weiler, Walter Maetzler, Justina Dargvainiene, Kim Falk, Sarah Philippen, Thorsten Bartsch, Charlotte Flueh, Christoph Roecken, Bettina Moeller, Georg Royl, Alexander Neumann, Norbert Brueggemann, Benjamin Roeben, Claudia Schulte, Benjamin Bender, Daniela Berg, Gregor Kuhlenbaeumer

Summary: This study compared the clinical, radiological, and cerebrospinal fluid marker data of patients with CAA, MLH, AD, and healthy controls. The results showed that cSS was more common in CAA, and MLH with cSS was associated with ICH. The concentrations of cerebrospinal fluid markers differed among the groups.

INTERNATIONAL JOURNAL OF STROKE (2023)

Article Clinical Neurology

Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study

Bernd Leplow, Daniela Renftle, Mareike Thomas, Katja Michaelis, Susanne Solbrig, Walter Maetzler, Daniela Berg, Inga Liepelt-Scarfone

Summary: Impulse control disorders (ICD) frequently occur in Parkinson's disease (PD), not always as a direct consequence of medication. This study investigated premorbid personality traits and behavioral characteristics in non-demented PD patients with self-reported symptoms of ICD (PD-srICD). It was found that patients with PD-srICD had similarities with substance use disorder patients, and thorough psychological diagnostics are recommended.

JOURNAL OF NEURAL TRANSMISSION (2023)

Article Neurosciences

Motor cortical excitability and pre-supplementary motor area neurochemistry in healthy adults with substantia nigra hyperechogenicity

Gabrielle Todd, Caroline D. Rae, Janet L. Taylor, Nigel C. Rogasch, Jane E. Butler, Michael Hayes, Robert A. Wilcox, Simon C. Gandevia, Karl Aoun, Adrian Esterman, Simon J. G. Lewis, Julie M. Hall, Elie Matar, Jana Godau, Daniela Berg, Christian Plewnia, Anna-Katharina Von Thaler, Clarence Chiang, Kay L. Double

Summary: Research has found that increased thickness of the substantia nigra in healthy older adults may be associated with changes in excitability of motor cortical circuitry. This finding has important implications for understanding brain changes in healthy older adults at risk of Parkinson's disease.

JOURNAL OF NEUROSCIENCE RESEARCH (2023)

Letter Clinical Neurology

Confusion of evidence-based reviews and guidelines

Gunther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Anette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Introduction to Gene Therapy

Thomas Gasser

Summary: After years of research and setbacks, gene therapies have achieved undeniable success by directly modifying genetic information on the DNA or RNA level. Both ex vivo strategies, manipulating patient cells outside the body, and in vivo approaches have been successful. In addition to gene supplementation, the use of the CRISPR-Cas9 system for altering nuclear DNA sequences and interfering with the transcriptional process on the RNA level can also be considered as gene therapies in a broad sense.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2023)

Review Clinical Neurology

The heterogeneity of Parkinson's disease

Ullrich Wuellner, Per Borghammer, Chi-un Choe, Ilona Csoti, Bjorn Falkenburger, Thomas Gasser, Paul Lingor, Peter Riederer

Summary: The heterogeneity of Parkinson's disease presents challenges for future research and therapeutic design. Various pathophysiological concepts and mechanisms, including alpha-synuclein misfolding, oxidative stress, and microbial agents, may contribute to the development of PD. The unresolved heterogeneity of PD has hindered previous clinical trials, highlighting the need for personalized therapeutic approaches.

JOURNAL OF NEURAL TRANSMISSION (2023)

Review Clinical Neurology

Genetic testing for Parkinson's disease in clinical practice

Thomas Gasser

Summary: The identification of disease-causing mutations or strong risk factors for Parkinson's disease in specific genes has led to a better understanding of disease pathogenesis. Many gene and mutation-specific targeted disease-modifying treatments are being developed and studied. Therefore, it is important to raise awareness and offer genetic testing to patients considering innovative trials.

JOURNAL OF NEURAL TRANSMISSION (2023)

Article Clinical Neurology

Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers

Pierre-Emmanuel Sugier, Elise A. Lucotte, Cloe Domenighetti, Matthew H. Law, Mark M. Iles, Kevin Brown, Christopher Amos, James D. McKay, Rayjean J. Hung, Mojgan Karimi, Delphine Bacq-Daian, Anne Boland-Auge, Robert Olaso, Jean-francois Deleuze, Fabienne Lesueur, Evgenia Ostroumova, Ausrele Kesminiene, Florent de Vathaire, Pascal Guenel, Ashwin Ashok Kumar Sreelatha, Claudia Schulte, Sandeep Grover, Patrick May, Dheeraj R. Bobbili, Milena Radivojkov-Blagojevic, Peter Lichtner, Andrew B. Singleton, Dena G. Hernandez, Connor Edsall, George D. Mellick, Alexander Zimprich, Walter Pirker, Ekaterina Rogaeva, Anthony E. Lang, Sulev Koks, Pille Taba, Suzanne Lesage, Alexis Brice, Jean-Christophe Corvol, Marie-Christine Chartier-Harlin, Eugenie Mutez, Kathrin Brockmann, Angela B. Deutschlaender, Georges M. Hadjigeorgiou, Efthimios Dardiotis, Leonidas Stefanis, Athina Maria Simitsi, Enza Maria Valente, Simona Petrucci, Letizia Straniero, Anna Zecchinelli, Gianni Pezzoli, Laura Brighina, Carlo Ferrarese, Grazia Annesi, Andrea Quattrone, Monica Gagliardi, Hirotaka Matsuo, Akiyoshi Nakayama, Nobutaka Hattori, Kenya Nishioka, Sun Ju Chung, Yun Joong Kim, Pierre Kolber, Bart P. C. van de Warrenburg, Bastiaan R. Bloem, Jan Aasly, Mathias Toft, Lasse Pihlstrom, Leonor Correia Guedes, Joaquim J. Ferreira, Soraya Bardien, Jonathan Carr, Eduardo Tolosa, Mario Ezquerra, Pau Pastor, Monica Diez-Fairen, Karin Wirdefeldt, Nancy Pedersen, Caroline Ran, Andrea C. Belin, Andreas Puschmann, Emil Ygland Roedstroem, Carl E. Clarke, Karen E. Morrison, Manuela Tan, Dimitri Krainc, Lena F. Burbulla, Matt J. Farrer, Rejko Kruger, Thomas Gasser, Manu Sharma, Therese Truong, Alexis Elbaz

Summary: By using genome-wide association studies, this study found that Parkinson's disease (PD) is genetically correlated with melanoma and prostate cancer, while it is inversely correlated with ovarian cancer. These findings suggest that pleiotropic genes contribute to the association between PD and specific cancers.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy

Anastasia Kuzkina, Celine Panzer, Aline Seger, Daniela Schmitt, Jonas Roessle, Sebastian R. Schreglmann, Henrike Knacke, Elena Salabasidou, Antonia Kohl, Elisabeth Sittig, Michael Barbe, Daniela Berg, Jens Volkmann, Claudia Sommer, Wolfgang H. Oertel, Eva Schaeffer, Michael Sommerauer, Annette Janzen, Kathrin Doppler

Summary: The study assessed the use of RT-QuIC method to detect alpha-synuclein aggregation in skin biopsy samples of iRBD patients. It was found that 97.4% of iRBD patients, 87.2% of PD patients, and 13% of controls showed aggregation of alpha-synuclein. RT-QuIC was more sensitive but less specific compared to immunohistochemistry.

MOVEMENT DISORDERS (2023)

Letter Clinical Neurology

Confusion of Evidence-Based Reviews and Guidelines

Guenther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Anette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

MOVEMENT DISORDERS (2023)

Article Multidisciplinary Sciences

Bayesian network modeling of risk and prodromal markers of Parkinson's disease

Meemansa Sood, Ulrike Suenkel, Anna-Katharina von Thaler, Helena U. U. Zacharias, Kathrin Brockmann, Gerhard W. Eschweiler, Walter Maetzler, Daniela Berg, Holger Froehlich, Sebastian Heinzel

Summary: Parkinson's disease (PD) has a long prodromal phase with many markers indicating an increased risk prior to clinical diagnosis. Current prediction models lack consideration of interdependencies between predictors and differentiation by subtypes, and may be limited by confounding factors and restricted data access. Using AI and a Bayesian network, we analyzed data from 1178 healthy individuals and 24 incident PD cases to quantify marker interdependencies and generate synthetic profiles. We identified robust interdependencies and demonstrated the usefulness of AI in modeling and understanding PD markers.

PLOS ONE (2023)

Article Clinical Neurology

The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Stephan Greten, Florian Wegner, Ida Jensen, Lea Krey, Sophia Rogozinski, Meret Fehring, Johanne Heine, Johanna Doll-Lee, Monika Poetter-Nerger, Molly Zeitzschel, Keno Hagena, David J. Pedrosa, Carsten Eggers, Katrin Buerk, Claudia Trenkwalder, Inga Claus, Tobias Warnecke, Patrick Suess, Juergen Winkler, Doreen Gruber, Florin Gandor, Daniela Berg, Steffen Paschen, Joseph Classen, Elmar H. Pinkhardt, Jan Kassubek, Wolfgang H. Jost, Lars Toenges, Andrea A. Kuehn, Johannes Schwarz, Oliver Peters, Eman Dashti, Josef Priller, Eike J. Spruth, Patricia Krause, Annika Spottke, Anja Schneider, Aline Beyle, Okka Kimmich, Markus Donix, Robert Haussmann, Moritz Brandt, Elisabeth Dinter, Jens Wiltfang, Bjoern H. Schott, Inga Zerr, Mathias Baehr, Katharina Buerger, Daniel Janowitz, Robert Perneczky, Boris-Stephan Rauchmann, Endy Weidinger, Johannes Levin, Sabrina Katzdobler, Emrah Duezel, Wenzel Glanz, Stefan Teipel, Ingo Kilimann, Johannes Prudlo, Thomas Gasser, Kathrin Brockmann, Daniel C. Hoffmann, Thomas Klockgether, Olaf Krause, Johannes Heck, Guenter U. Hoeglinger, Martin Klietz

Summary: This study explored the pattern of comorbidities and co-medication in PSP patients. It found that PSP patients have a higher prevalence of cardiovascular diseases and diabetes, and they receive a greater number of drugs, leading to a higher prevalence of polypharmacy.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Nir Giladi, Roy N. Alcalay, Gary Cutter, Thomas Gasser, Tanya Gurevich, Guenter U. Hoeglinger, Kenneth Marek, Claudio Pacchetti, Anthony H. Schapira, Clemens R. Scherzer, Tanya Simuni, Pascal Minini, S. Pablo Sardi, M. Judith Peterschmitt

Summary: The safety, efficacy, and target engagement of venglustat in early-stage Parkinson's disease patients with GBA1 variants were assessed. The study showed that venglustat had a satisfactory safety profile but did not show beneficial treatment effect compared with placebo. These findings suggest that glucosylceramide synthase inhibition with venglustat may not be a viable therapeutic approach for GBA1-associated Parkinson's disease.

LANCET NEUROLOGY (2023)

Review Clinical Neurology

DNAJC12 in Monoamine Metabolism, Neurodevelopment, and Neurodegeneration

Isaac Bul Deng, Jordan Follett, Mengfei Bu, Matthew J. Farrer

Summary: Recent studies have shown that pathogenic variants in DNAJC12 can cause various diseases, including mild hyperphenylalaninemia, infantile dystonia, young-onset parkinsonism, developmental delay and cognitive deficits. DNAJC12 has been included in newborn screening, particularly in Spain, emphasizing the importance of genetic diagnosis and early intervention. However, many practitioners may not be aware of these advances, and molecular testing for DNAJC12 is yet to be conducted for many patients, especially adults. This review provides a summary of genotype-phenotype relationships and treatment approaches for patients with pathogenic variants in DNAJC12, as well as an overview of the protein's structure, known genetic variants, domains, binding partners, and its role in monoamine synthesis, disease etiology, and pathogenesis.

MOVEMENT DISORDERS (2023)

Letter Clinical Neurology

Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease

Christos Koros, Kathrin Brockmann, Athina-Maria Simitsi, Anastasia Bougea, Hui Liu, Ann-Kathrin Hauser, Claudia Schulte, Stefanie Lerche, Ioanna Pachi, Nikolaos Papagiannakis, Roubina Antonelou, Athina Zahou, Isabel Wurster, Efthymia Efthymiopoulou, Ion Beratis, Matina Maniati, Marina Moraitou, Helen Michelakakis, Georgios Paraskevas, Sokratis G. Papageorgiou, Constantin Potagas, Dimitra Papadimitriou, Maria Bozi, Maria Stamelou, Thomas Gasser, Leonidas Stefanis

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

The semicircular canal function is preserved with little impact on falls in patients with mild Parkinson's disease

Jun-Pyo Hong, Hanim Kwon, Euyhyun Park, Sun-Uk Lee, Chan-Nyoung Lee, Byung-Jo Kim, Ji-Soo Kim, Kun-Woo Park

Summary: In patients with mild-to-moderate PD, vestibular function assessed by video head-impulse tests appears relatively preserved and has minimal impact on the risk of falls. Risk of postural instability is associated with the severity of clinical symptoms in PD.

PARKINSONISM & RELATED DISORDERS (2024)

Article Clinical Neurology

Estimating the sequence of biomarker changes in Parkinson's disease

Yaqin Xiang, XiuRong Huang, Qian Xu, Zhenhua Liu, Yase Chen, Qiying Sun, Junling Wang, Hong Jiang, Lu Shen, Xinxiang Yan, Beisha Tang, Jifeng Guo

Summary: Using the novel data-driven method DEBM, this study determined the sequence of several common biomarker changes in Parkinson's disease (PD). The left putamen was found to be the earliest biomarker to become abnormal, followed by the right putamen, CSF alpha-synuclein, right caudate, left caudate, and serum NfL. The estimated disease stages showed significant differences between PD and healthy controls, and achieved a high accuracy for distinguishing PD from HC.

PARKINSONISM & RELATED DISORDERS (2024)

Article Clinical Neurology

Incidence and risk factors of institutionalisation in Parkinson's disease and atypical parkinsonism

Yan Li, David J. McLernon, Carl E. Counsell, Angus D. Macleod

Summary: This study aimed to investigate the incidence and risk factors for institutionalisation in Parkinson's disease (PD) and atypical parkinsonism (AP). The study found that institutionalisation was more frequent in AP compared to PD and controls. Age, poorer cognition, and more-severe parkinsonian impairment were independent predictors of institutionalisation.

PARKINSONISM & RELATED DISORDERS (2024)